The nation of Zimbabwe has turned down a substantial US healthcare agreement valued at $367m (272 million pounds) over five years because of Washington's request for confidential information.
The decision came to light after a official document from December was disclosed, indicating that Head of State Emmerson Mnangagwa felt the arrangement was "lopsided".
A government representative has since clarified that the United States was seeking health data for research and profit but was not willing to share the resulting advantages from future medical innovations.
"We must now begin the challenging and unfortunate process of scaling back our support in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont in a statement.
Her embassy indicated the US had provided over $1.9bn in health funding to Zimbabwe over the last two decades.
A doctors' association in Zimbabwe has called for more dialogue to secure a deal suitable to all parties so the nation's vital HIV treatment initiative can be sustained.
Broader Background
This rejection follows a comparable case in Kenya, where a court halted a related deal with the US following concerns were raised about the security of citizens' medical information.
After returning to the presidency recently, US President Donald Trump has reduced foreign aid and shut down the key foreign aid agency.
USAID had administered assistance for the American government, but Trump stated its spending was "inefficient" and his government was pursuing direct bilateral agreements to boost openness and accountability.
Based on reports, Sixteen African countries have so far agreed to these new agreements, constituting more than $18.3bn in new funding.
Details of the Declined Deal
The funds for Zimbabwe was intended to funded "HIV/Aids treatment and prevention, TB, malaria, maternal and child health, and disease outbreak preparedness.
"It is our view this collaboration would have delivered significant advantages for Zimbabwean communities, particularly the 1.2 million men, women and children presently on antiretroviral therapy via American-funded programmes," the Ambassador commented.
However, official spokesman Nick Mangwana argued the arrangement was "unfair".
"Our nation was requested to share its genetic material and health information for a long time, without any equivalent promise of benefiting from any medical innovations – like vaccines, diagnostics, or treatments – that could result from that shared data," his statement read.
"Effectively, our nation would supply the raw materials for scientific discovery without any certainty that the resulting innovations would be accessible to our people should a future disease outbreak emerge."
Sovereignty and International Frameworks
He also noted that the US's withdrawal from the World Health Organization (WHO) and its pursuit of one-on-one deals were upending frameworks previously set up through the international health agency.
The spokesperson gave as an example its Pathogen Access and Benefit Sharing framework designed to manage potential pandemics.
"This mechanism is designed to ensure that when a country contributes its data, the resulting advantages – such as medicines and cures – are distributed fairly, not commercialised solely by those with the capability to create them."
The government's concerns regarding the US deal "should not be misconstrued as hostility towards the US," he added.
"We are open to continued discussions with our American counterparts on how future co-operation might be arranged in a way that respects the independence and interests of each country."
Medical Community Response
Medical experts said it understood the government's concerns, but suggested that talks should continue since a large portion of the nation's HIV programmes relied on foreign aid.
"If technical issues arise, such as those relating to information security or implementation frameworks, these can often be addressed via detailed discussion and negotiated safeguards," it added.
The halted deal underscores the complex tensions between receiving much-needed foreign assistance and safeguarding local interests in an increasingly data-driven world.